Jump to any asset
849 assets, updated daily
As of September 16, 2026, Danaher Corp. (DHR) trades at $209.36. CleaRank Financial AI rates it Hold with a fair value of $209.36, in line with the current price. Wall Street's consensus target is $230.00 across 26 analysts. RSI at 40 is in neutral territory, and the price is above its 50-day average of $202.80.
Danaher Corp. (DHR)
Danaher Corp. NYSE
$209.36
6.110 (3.01%)
At close: Sep 15, 4:00 PM EDT
AI Analyst Consensus
59 / 100
Danaher Corp. (DHR) is currently trading at $209.36, with its fair value assessment aligning with the current price, indicating no immediate upside from a valuation perspective. The company operates within the Healthcare sector, specifically in Diagnostics & Research, and its performance is closely watched by investors. While Wall Street maintains a 'Buy' consensus with a median price target of $230, suggesting a 9.9% upside, significant insider selling activity presents a notable risk. Over $507 million in sales by insiders in recent filings signals a potential lack of confidence or a strategic divestiture, which warrants caution. Despite the insider selling, Danaher's fundamentals remain relatively stable. Its price-to-sales ratio of 5.69 is slightly above the sector median of 3.7, and its return on equity at 7.61% is also higher than the sector average of 6.9%. The company's revenue growth of 5.5% is below the sector median of 8.1%, but its profit margin of 15.95% and operating margin of 19.78% indicate strong operational efficiency. The current price is trading above its 50-day and 200-day moving averages ($202.80 and $202.17), suggesting a generally positive short-to-medium term trend, though the RSI at 40.47 indicates neutral momentum.
DHR Price Analysis
Market Metrics
Open
$203.08
Day Range
$202.62 to $209.55
Prev Close
$203.25
Volume
3.50M
52-Week Range
$160.93 to $242.80
Market Cap
$147.18B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (14% difference), suggesting fair market pricing relative to industry standards.
DHR Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 3 quarters, DHR beat estimates 2 times. However, the stock fell 1 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
DHR Analysis
Company's Health
4/5
12-Month Analyst Target
+9.86% Upside
Median of 26 analysts (12-month)
$230.00
AI Technical Analysis
Danaher Corp. (DHR) is currently trading above its 50-day SMA of $202.80 and its 200-day SMA of $202.17, indicating a generally positive trend. The price is also above its 20-day EMA of $206.80. The Relative Strength Index (RSI) is at 40.47, which falls into the 'Neutral' momentum category, suggesting neither overbought nor oversold conditions. The MACD is slightly positive at 0.317, indicating some upward momentum. Volume on the latest trading day was 3,504,900, which is approximately 12.9% above the average daily volume of 3,105,470, suggesting increased investor interest. Key support levels are indicated by the moving averages, while the current price action suggests a neutral to slightly bullish short-term outlook. However, the lack of strong bullish or bearish signals from momentum indicators like the RSI suggests a period of consolidation or indecision.
ProTips
- Monitor insider transaction activity closely, as the recent heavy selling pressure from insiders warrants caution despite positive analyst ratings.
- Given the neutral RSI reading, consider waiting for a clearer technical signal or a more attractive entry point before initiating a new position.
- The company's revenue growth is currently below sector averages; focus on its ability to innovate and expand market share to drive future top-line performance.
Key Catalysts
Bearish
Heavy Insider Selling Activity
Insiders have sold over $507.5 million worth of Danaher Corp. (DHR) stock across 71 transactions, indicating significant divestiture pressure that could negatively impact stock performance.
Source: Insider TransactionsNeutral
Mixed Earnings Performance
Danaher Corp. (DHR) has shown inconsistent earnings beats and misses in recent quarters, creating uncertainty around future earnings predictability and potentially limiting upside momentum.
Source: Earnings ReportsNeutral
Below Sector Average Revenue Growth
Danaher Corp.'s (DHR) revenue growth of 5.5% lags behind the healthcare sector median of 8.1%, suggesting potential challenges in market expansion or competitive positioning.
Source: Company FilingsBullish
Positive Wall Street Analyst Sentiment
A significant majority of Wall Street analysts maintain a 'Buy' rating on Danaher Corp. (DHR), with a median price target of $230, suggesting confidence in the company's future prospects.
Source: Analyst RatingsMarket Outlook
Danaher Corp. (DHR) is expected to maintain a stable outlook over the next 6-12 months, with its fair value assessment currently aligning with its trading price of $209.36. The median analyst target price of $230 suggests a potential upside of approximately 9.9%, reflecting Wall Street's confidence in the company's underlying business and its position within the healthcare sector. The company's strong profit margins and efficient operations provide a solid foundation for continued performance. However, the significant insider selling activity presents a considerable headwind and introduces an element of uncertainty. Should this selling pressure continue or intensify, it could weigh on the stock price, potentially negating the upside suggested by analyst targets. Conversely, any positive developments in revenue growth acceleration or successful integration of new technologies could serve as upside catalysts, potentially driving the stock towards the higher end of analyst price targets.
Key Statistics
| Market Cap | 147.18B |
|---|---|
| P/E Ratio | 36.29 |
| EPS (TTM) | 5.60 |
| Dividend Yield | 0.69% |
| 52 Week High | 242.80 |
| 52 Week Low | 160.93 |
Danaher Corp. (DHR) presents a mixed fundamental picture when compared to its Healthcare sector peers. Its Price-to-Sales (P/S) ratio stands at 5.69, which is higher than the sector median of 3.7, suggesting the stock may be trading at a premium on a revenue basis. The company's Return on Equity (ROE) is 7.61%, exceeding the sector median of 6.9%, indicating efficient use of shareholder equity. Profitability metrics are strong, with a net profit margin of 15.95% and an operating margin of 19.78%, both of which are strong. However, its revenue growth of 5.5% lags behind the sector median of 8.1%. The debt-to-equity ratio of 0.53 is in line with the sector average, suggesting a balanced capital structure. While the company demonstrates strong profitability and efficiency, its growth rate is somewhat subdued compared to industry averages, and its valuation appears stretched on a P/S basis.
Earnings & Growth Analysis
Danaher Corp. (DHR) has shown mixed earnings performance in its recent reported quarters. For the quarter ending June 2026, the company reported an EPS of $1.17, beating the estimate of $1.10 by 6.36%, though the stock saw a slight decline of -0.58%. Prior to that, the quarter ending March 2026 saw an EPS of $2.72, surpassing estimates by 6.67% and resulting in a positive price change of 0.42%. However, an earlier quarter to June 2026 reported a negative EPS surprise of -14.29% (-$0.16 actual vs -$0.14 estimate), leading to a price increase of 1.54%. This pattern suggests inconsistent earnings beats and misses, making future earnings a point of uncertainty.
Key Risks
The most significant risk for Danaher Corp. (DHR) is the heavy insider selling, with over $507 million in sales across 71 transactions, signaling potential negative sentiment from management. Additionally, the company's revenue growth of 5.5% is below the sector median, indicating potential challenges in expanding its top line. The stock's Price-to-Sales ratio of 5.69 is also higher than the sector average, suggesting a potentially overvalued position relative to its revenue generation.
Technical Indicators
| RSI (14) | 40.47 |
|---|---|
| MACD | 0.32 |
| SMA 50 | 202.80 |
| SMA 200 | 202.17 |
RSI
Neutral
SMA Cross
Neutral
Price vs SMA
Bullish
MACD
Bullish
Price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.40
Weak correlation
Nasdaq 100 (QQQ)
+0.28
Weak correlation
Bitcoin (BTC)
-0.03
Weak correlation
Gold (XAU)
+0.00
Weak correlation
Check Custom Correlation
How does any other asset move with DHR? One year of daily closes, Pearson correlation.
Try
DHR Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$207.27
Slight discount to current
Wait for small dip
Aggressive
$209.36
At current price
Enter now if confident
Risk Management
STOP LOSS
$196.63
MAX LOSS
-5.1%
Volatility-Adjusted Stop Loss
Calculated based on RSI (40.5) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$213.48
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$217.63
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$223.85
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for DHR is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 16, 2026.Growth of $10,000
A $10,000 investment in DHR in September 2016 would be worth about $30,842 today, compared with about $35,497 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in DHR today could grow to about $24,865 by 2036 in the base case, with a bull case near $71,810 and a bear case around $8,610. Projections are statistical simulations, not guarantees.
DHR Stock Price Prediction: 2030
CleaRank's simulation projects a price near $301 for DHR by 2030 in the base case, from $209 today (1.4x over 4 years). The downside path ends near $154. These are outcomes of a Monte Carlo simulation run on DHR's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $164 | $229 | $321 |
| 2028 | $156 | $251 | $404 |
| 2029 | $154 | $275 | $492 |
| 2030 | $154 | $301 | $589 |
| 2031 | $156 | $330 | $699 |
| 2032 | $159 | $362 | $822 |
| 2033 | $163 | $396 | $962 |
| 2034 | $168 | $434 | $1,120 |
| 2035 | $174 | $475 | $1,300 |
| 2036 | $180 | $521 | $1,503 |
Method: 10,000 simulated price paths using DHR's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
DHR Insider Trading Analysis
Bought
None
No open-market buys
Sold
$507.5M
13 Transactions
Insiders
25
Active Traders
Avg Transaction
$39.0M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 4, 2021 | RALES MITCHELL P
Officer and Director
|
Sell | 1.2M | $377.9M |
| May 12, 2025 | RALES STEVEN M
Chairman of the Board
|
Sell | 1.3M | $245.9M |
| Oct 31, 2025 | RALES MITCHELL P
Officer and Director
|
Sell | 600.0K | $129.6M |
| Nov 12, 2025 | RALES MITCHELL P
Officer and Director
|
Sell | 437.0K | $95.6M |
| Jul 24, 2020 | JOYCE THOMAS PATRICK JR
Chief Executive Officer
|
Sell | 181.4K | $35.2M |
| May 24, 2019 | DANIEL WILLIAM K II
Officer
|
Sell | 164.2K | $21.7M |
| Jan 31, 2020 | JOYCE THOMAS PATRICK JR
Chief Executive Officer
|
Sell | 132.5K | $21.5M |
| Jul 27, 2020 | COMAS DANIEL L
Officer
|
Sell | 100.0K | $19.5M |
| Aug 31, 2020 | LALOR ANGELA S
Officer
|
Sell | 77.9K | $16.0M |
| Feb 3, 2020 | COMAS DANIEL L
Officer
|
Sell | 82.5K | $13.3M |
Page 1 of 1
Frequently Asked Questions
Is Danaher Corp. stock a buy right now?
Danaher Corp. (DHR) is currently rated as 'Hold' by our consensus, with a score of 59. While Wall Street analysts largely recommend 'Buy' with a median price target of $230, significant insider selling and below-sector-average revenue growth present considerable risks that temper a strong buy recommendation.
What is Danaher Corp.'s stock price forecast for 2030?
Based on Monte Carlo simulations, Danaher Corp.'s (DHR) stock price forecast for 2030 shows a base case of $301.39, a downside projection of $154.10, and an upside projection of $589.44. These figures represent statistical outcomes and are not definitive price targets.
How does Danaher Corp. compare to its sector averages?
Danaher Corp. (DHR) shows a higher Return on Equity (7.61%) and Profit Margin (15.95%) compared to sector medians (ROE 6.9%, PS 3.7). However, its revenue growth (5.5%) trails the sector median (8.1%), and its P/S ratio (5.69) is above the sector average.
What are the main concerns for Danaher Corp. investors?
The primary concern for Danaher Corp. (DHR) investors is the substantial insider selling, totaling over $507 million, which raises questions about management's confidence. Additionally, the company's revenue growth is lagging behind its healthcare sector peers.
What is the Wall Street consensus on Danaher Corp. stock?
Wall Street analysts collectively hold a 'Buy' rating on Danaher Corp. (DHR), with 5 analysts rating it 'Strong Buy' and 17 rating it 'Buy'. The consensus score is 76 out of 100, and the median price target is $230, suggesting a potential upside of 9.9% from the current price.
What has been Danaher Corp.'s recent earnings performance?
Danaher Corp. (DHR) has experienced mixed earnings results recently. While it beat estimates for the quarter ending March 2026 and one quarter ending June 2026, another quarter ending June 2026 showed a negative EPS surprise. This inconsistency warrants close monitoring of future earnings reports.
Are there any significant catalysts expected for Danaher Corp.?
While no specific upcoming catalysts are detailed, Danaher Corp.'s (DHR) performance will likely be influenced by its ability to execute on its growth strategies and manage operational efficiencies. Investors should monitor company announcements for potential new contracts or strategic initiatives within the diagnostics and research space.